FIELD: medicine.
SUBSTANCE: invention relates to application of methylxanthine compound, in particular theophylline in day dose from 0.1 to 25 mg, and glucocorticoid in composition for treatment of chronic respiratory disease, such as chronic obstructive lung disease, asthma, composition being introduced into organism by inhalation method for its delivery into lungs.
EFFECT: combination of methylxanthine compound in low dose and glucocorticoid ensures synergetic effect with respect to improvement of lung function and reduction of inflammation.
19 cl,1 tbl, 5 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| MEDICATIONS FOR CHRONIC RESPIRATORY DISEASE TREATMENT | 2005 |
|
RU2395284C2 |
| TREATMENT OF PATIENTS SUFFERING FROM BRONCHIAL ASTHMA | 2008 |
|
RU2356544C1 |
| COMBINATIONS CONTAINING ANTIMUSCARINE AGENTS AND CORTICOSTEROIDS | 2005 |
|
RU2385721C2 |
| COMBINATIONS FOR TREATMENT OF INFLAMMATORY DISEASES | 2002 |
|
RU2300379C2 |
| PHARMACEUTICAL COMPOSITIONS | 2011 |
|
RU2568882C2 |
| AEROSOL PHARMACEUTICAL COMPOSITION, A METHOD OF TREATMENT OF PATIENTS WITH RESPIRATORY DISEASES | 1992 |
|
RU2129424C1 |
| METHOD FOR FORECASTING THE DURATION OF ISCHEMIA OF MYOCARDIUM IN PATIENTS WITH COPD WITH COPD AND RELATED CHD | 2016 |
|
RU2625028C1 |
| APPLICATION OF H, K-ATPase INHIBITOR FOR TREATING NASAL POLYPS | 1997 |
|
RU2197966C2 |
| USING GLUCOCORTICOID COMPOSITION FOR TREATING SEVERE AND UNCONTROLLED ASTHMA | 2010 |
|
RU2519344C2 |
| CRYSTALLINE LEVOSALBUTAMOL SULFATE, METHOD OF ITS OBTAINING AND PHARMACEUTICAL COMPOSITION, WHICH CONTAINS IT | 2005 |
|
RU2440972C2 |
